Ben Leach

Combining paclitaxel with the investigational compound neratinib increased response rates versus neratinib alone in patients with HER2-positive metastatic breast cancer.

Acute myeloid leukemia is potentially driven by at least one genetic mutation in nearly all cases, with a complex interaction of multiple genetic events contributing to the development of the disease

A phase II study has found that denosumab was able to halt progression in the vast majority of enrolled patients with giant cell tumor of the bone as well as reducing the need for surgery.

Researchers at the National Cancer Institute have developed a comprehensive analysis of coding variants in nine of the most frequently studied human tumor cell lines in cancer research.

The FDA has approved afatinib, along with a companion diagnostic, to treat patients with metastatic non-small cell lung cancer who express specific types of EGFR mutations.

A new drug application has been submitted for ibrutinib as a therapy for previously treated CLL and MCL after positive results showed high response rates to the drug in two clinical trials.

The FDA has granted priority review to a regimen of pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive early-stage breast cancer.

Patients with chronic lymphocytic leukemia and mantle cell lymphoma showed high response rates to therapy with the novel targeted therapy ibrutinib, further solidifying the safety and efficacy of a drug that has proven very promising in early clinical trials.

Patients with previously treated multiple myeloma responded well to therapy with the monoclonal antibody elotuzumab in combination with lenalidomide and low-dose dexamethasone, with a high objective response rate and longer progression-free survival.

The quest to deliver optimal radiation therapy for patients with prostate cancer has led to a variety of advances in technologies and techniques, yet key questions remain unanswered.

After years of varying decisions by lower courts regarding the patents held on a test for genetic mutations associated with breast cancer, the US Supreme Court has ruled that a segment of DNA in isolation is a natural product and not eligible for patent protection.

Treatment with the investigational agent trebananib resulted in a significant reduction in the risk of progression or death in patients with recurrent ovarian cancer, according to a phase III study.

The FDA has rejected a new drug application for tivozanib for the treatment of advanced renal cell carcinoma, recommending an additional clinical trial to address concerns over existing clinical data.

A new study suggests that germline mutations of BRCA1/2 could play a significant role in more-aggressive cases of prostate cancer. Additionally, BRCA2 mutations were specifically linked to poor overall survival.

The immunomodulatory agent lenalidomide is now approved by the FDA to treat patients with mantle cell lymphoma who have relapsed or whose disease has progressed after two prior therapies including at least one prior treatment with bortezomib.

Low-dose weekly paclitaxel is as effective and has fewer side effects than the standard biweekly schedule for patients with early-stage breast cancer.

Adding bevacizumab to a standard treatment regimen for glioblastoma consisting of chemoradiation with temozolomide in newly diagnosed patients does not improve OS and did not significantly improve PFS.

Adding the white blood cell booster granulocyte-macrophage colony-stimulating factor to the immunotherapy ipilimumab extended survival in patients with metastatic melanoma when compared with ipilimumab alone and may be a safer alternative than monotherapy.

The FDA approved both dabrafenib and trametinib for the treatment of patients with metastatic or unresectable melanoma, as well as a companion diagnostic to properly identify the patients exhibiting the mutations that are targeted by these agents.

The FDA has granted priority review to nab-paclitaxel in combination with gemcitabine for the first-line treatment of patients with metastatic pancreatic cancer.

A new study has confirmed that low testosterone is a side effect in a large proportion of patients who received crizotinib for the treatment of ALK-positive non–small cell lung cancer.

A late-stage trial investigating inotuzumab ozogamicin as a treatment for patients with aggressive non-Hodgkin lymphoma has been halted after interim data showed the agent was unlikely to improve survival.

A new measure of tumor heterogeneity in patients with head and neck squamous cell carcinoma (HNSCC) was significantly associated with tumor progression and adverse treatment outcomes.

While chemotherapy might initially be effective in the treatment of patients with metastatic breast cancer, it is very common for patients to develop resistance to such agents.

Researchers are attempting to determine if targeting more than one tyrosine kinase provide a greater benefit in several clinical trials involving the investigational drug afatinib.

A high-profile case of a medical decision being based primarily on the results of a genetic test has prompted a national discussion on the benefits and risks associated with acting on the results of such a test.

The novel selective PI3K-delta inhibitor idelalisib produced rapid and prolonged tumor shrinkage in patients with relapsed or refractory chronic lymphocytic leukemia who received the drug as a monotherapy.

The FDA approved radium RA 223 dichloride for the treatment of symptomatic metastatic castration-resistant prostate cancer that has spread to the bones but not to any other organs.

The I-SPY trials are designed to test several different experimental therapies at once to determine which ones work best in which patients.

A single clinical trial was deemed insufficient to support approval of tivozanib for the treatment of patients with advanced renal cell carcinoma, according to a 13-1 vote by the FDA's Oncologic Drugs Advisory Committee.